Item Type | Name |
Concept
|
Ovarian Neoplasms
|
Academic Article
|
Integrin alpha(v)beta(3)/vitronectin interaction affects expression of the urokinase system in human ovarian cancer cells.
|
Academic Article
|
Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer.
|
Academic Article
|
Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer.
|
Academic Article
|
Let-7 prevents early cancer progression by suppressing expression of the embryonic gene HMGA2.
|
Academic Article
|
Does equal treatment yield equal outcomes? The impact of race on survival in epithelial ovarian cancer.
|
Academic Article
|
The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin.
|
Academic Article
|
An orally available small-molecule inhibitor of c-Met, PF-2341066, reduces tumor burden and metastasis in a preclinical model of ovarian cancer metastasis.
|
Academic Article
|
MMP-2 functions as an early response protein in ovarian cancer metastasis.
|
Academic Article
|
Effects of oral contraceptives or a gonadotropin-releasing hormone agonist on ovarian carcinogenesis in genetically engineered mice.
|
Academic Article
|
CD95 promotes tumour growth.
|
Academic Article
|
c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion.
|
Academic Article
|
A phase II, single-arm study of the anti-a5ß1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer.
|
Academic Article
|
Let-7 expression defines two differentiation stages of cancer.
|
Academic Article
|
Let-7 modulates acquired resistance of ovarian cancer to Taxanes via IMP-1-mediated stabilization of multidrug resistance 1.
|
Academic Article
|
Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target.
|
Academic Article
|
Ligand-independent activation of c-Met by fibronectin and a(5)ß(1)-integrin regulates ovarian cancer invasion and metastasis.
|
Academic Article
|
Foretinib (GSK1363089), an orally available multikinase inhibitor of c-Met and VEGFR-2, blocks proliferation, induces anoikis, and impairs ovarian cancer metastasis.
|
Academic Article
|
The effects of 17ß-estradiol and a selective estrogen receptor modulator, bazedoxifene, on ovarian carcinogenesis.
|
Academic Article
|
Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth.
|
Academic Article
|
{beta}3-integrin expression on tumor cells inhibits tumor progression, reduces metastasis, and is associated with a favorable prognosis in patients with ovarian cancer.
|
Academic Article
|
Targeting the urokinase plasminogen activator receptor inhibits ovarian cancer metastasis.
|
Academic Article
|
Involvement of a mitogen-activated protein kinase signaling pathway in the regulation of urokinase promoter activity by c-Ha-ras.
|
Academic Article
|
The first line of intra-abdominal metastatic attack: breaching the mesothelial cell layer.
|
Academic Article
|
Use of a novel 3D culture model to elucidate the role of mesothelial cells, fibroblasts and extra-cellular matrices on adhesion and invasion of ovarian cancer cells to the omentum.
|
Academic Article
|
The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2.
|
Academic Article
|
The molecular signature of endometriosis-associated endometrioid ovarian cancer differs significantly from endometriosis-independent endometrioid ovarian cancer.
|
Academic Article
|
Ovarian cancer development and metastasis.
|
Academic Article
|
HOXA9 promotes ovarian cancer growth by stimulating cancer-associated fibroblasts.
|
Academic Article
|
A novel multipurpose monoclonal antibody for evaluating human c-Met expression in preclinical and clinical settings.
|
Academic Article
|
Organotypic models of metastasis: A three-dimensional culture mimicking the human peritoneum and omentum for the study of the early steps of ovarian cancer metastasis.
|
Academic Article
|
Relationship of type II diabetes and metformin use to ovarian cancer progression, survival, and chemosensitivity.
|
Academic Article
|
miR-92a inhibits peritoneal dissemination of ovarian cancer cells by inhibiting integrin a5 expression.
|
Academic Article
|
Serial sectioning of the fallopian tube allows for improved identification of primary fallopian tube carcinoma.
|
Academic Article
|
MicroRNAs reprogram normal fibroblasts into cancer-associated fibroblasts in ovarian cancer.
|
Academic Article
|
Mesothelial cells promote early ovarian cancer metastasis through fibronectin secretion.
|
Academic Article
|
Expression of the homeobox gene HOXA9 in ovarian cancer induces peritoneal macrophages to acquire an M2 tumor-promoting phenotype.
|
Academic Article
|
Three-dimensional modeling of ovarian cancer.
|
Academic Article
|
Urokinase plasminogen activator system-targeted delivery of nanobins as a novel ovarian cancer therapy.
|
Academic Article
|
Epithelial ovarian cancer experimental models.
|
Academic Article
|
WNT7A/ß-catenin signaling induces FGF1 and influences sensitivity to niclosamide in ovarian cancer.
|
Academic Article
|
Statin therapy is associated with improved survival in patients with non-serous-papillary epithelial ovarian cancer: a retrospective cohort analysis.
|
Academic Article
|
Summary of the 2013 American Association for Cancer Research (AACR) Annual Meeting.
|
Academic Article
|
Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models.
|
Academic Article
|
Quantitative high throughput screening using a primary human three-dimensional organotypic culture predicts in vivo efficacy.
|
Academic Article
|
Whole-genome characterization of chemoresistant ovarian cancer.
|
Academic Article
|
The hypoxia-related microRNA miR-199a-3p displays tumor suppressor functions in ovarian carcinoma.
|
Academic Article
|
Glucocorticoid receptor activation inhibits chemotherapy-induced cell death in high-grade serous ovarian carcinoma.
|
Academic Article
|
Hyperglycemia-induced metabolic compensation inhibits metformin sensitivity in ovarian cancer.
|
Academic Article
|
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer.
|
Academic Article
|
Microenvironment-induced downregulation of miR-193b drives ovarian cancer metastasis.
|
Academic Article
|
Modeling the Early Steps of Ovarian Cancer Dissemination in an Organotypic Culture of the Human Peritoneal Cavity.
|
Academic Article
|
Integrative proteomic profiling of ovarian cancer cell lines reveals precursor cell associated proteins and functional status.
|
Academic Article
|
Metformin Targets Central Carbon Metabolism and Reveals Mitochondrial Requirements in Human Cancers.
|
Academic Article
|
Exosomes Promote Ovarian Cancer Cell Invasion through Transfer of CD44 to Peritoneal Mesothelial Cells.
|
Academic Article
|
Reversal of Chemoresistance in Ovarian Cancer by Co-Delivery of a P-Glycoprotein Inhibitor and Paclitaxel in a Liposomal Platform.
|
Academic Article
|
Genomics of Ovarian Cancer Progression Reveals Diverse Metastatic Trajectories Including Intraepithelial Metastasis to the Fallopian Tube.
|
Academic Article
|
Prolactin Receptor-Mediated Internalization of Imaging Agents Detects Epithelial Ovarian Cancer with Enhanced Sensitivity and Specificity.
|
Academic Article
|
Loss of BRCA1 in the Cells of Origin of Ovarian Cancer Induces Glycolysis: A Window of Opportunity for Ovarian Cancer Chemoprevention.
|
Academic Article
|
A High-Throughput Screening Model of the Tumor Microenvironment for Ovarian Cancer Cell Growth.
|
Academic Article
|
High glucocorticoid receptor expression predicts short progression-free survival in ovarian cancer.
|
Academic Article
|
Multi-level Proteomics Identifies CT45 as a Chemosensitivity Mediator and Immunotherapy Target in Ovarian Cancer.
|
Academic Article
|
Induction of Neoantigen-Specific Cytotoxic T Cells and Construction of T-cell Receptor-Engineered T Cells for Ovarian Cancer.
|
Academic Article
|
A 3D tumor microenvironment regulates cell proliferation, peritoneal growth and expression patterns.
|
Academic Article
|
Who are the long-term survivors of high grade serous ovarian cancer?
|
Academic Article
|
Adipocyte-induced CD36 expression drives ovarian cancer progression and metastasis.
|
Academic Article
|
The road to long-term survival: Surgical approach and longitudinal treatments of long-term survivors of advanced-stage serous ovarian cancer.
|
Academic Article
|
Fibroblasts Mobilize Tumor Cell Glycogen to Promote Proliferation and Metastasis.
|
Academic Article
|
The Tumor Microenvironment Takes Center Stage in Ovarian Cancer Metastasis.
|
Academic Article
|
Neutrophils facilitate ovarian cancer premetastatic niche formation in the omentum.
|
Academic Article
|
SPHK1 Is a Novel Target of Metformin in Ovarian Cancer.
|
Academic Article
|
Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference.
|
Academic Article
|
Proteomics reveals NNMT as a master metabolic regulator of cancer-associated fibroblasts.
|
Academic Article
|
Quantitative High-Throughput Screening Using an Organotypic Model Identifies Compounds that Inhibit Ovarian Cancer Metastasis.
|
Academic Article
|
Mesothelial Cell HIF1a Expression Is Metabolically Downregulated by Metformin to Prevent Oncogenic Tumor-Stromal Crosstalk.
|
Academic Article
|
Adipocyte-Induced FABP4 Expression in Ovarian Cancer Cells Promotes Metastasis and Mediates Carboplatin Resistance.
|
Academic Article
|
Are We Ready for Hyperthermic Intraperitoneal Chemotherapy in the Upfront Treatment of Ovarian Cancer?
|
Academic Article
|
Updates and New Options in Advanced Epithelial Ovarian Cancer Treatment.
|
Academic Article
|
The Ratio of Toxic-to-Nontoxic miRNAs Predicts Platinum Sensitivity in Ovarian Cancer.
|
Academic Article
|
Germline mutations in Black patients with ovarian, fallopian tube and primary peritoneal carcinomas.
|
Academic Article
|
Neoadjuvant Chemotherapy Induces Genomic and Transcriptomic Changes in Ovarian Cancer.
|
Academic Article
|
Resilience in the Face of Pandemic: The Impact of COVID-19 on the Psychologic Morbidity and Health-Related Quality of Life Among Women With Ovarian Cancer.
|
Academic Article
|
The adipocyte microenvironment and cancer.
|
Academic Article
|
Ovarian Masses: The Value of Acoustic Shadowing on Ultrasound Examination.
|
Academic Article
|
Cancer-associated mesothelial cell-derived ANGPTL4 and STC1 promote the early steps of ovarian cancer metastasis.
|
Academic Article
|
Understanding Long-Term Survival of Patients with Ovarian Cancer-The Tumor Microenvironment Comes to the Forefront.
|
Academic Article
|
Diagnostic Performance of Ultrasonography-Based Risk Models in Differentiating Between Benign and Malignant Ovarian Tumors in a US Cohort.
|
Academic Article
|
Adipocytes reprogram cancer cell metabolism by diverting glucose towards glycerol-3-phosphate thereby promoting metastasis.
|
Academic Article
|
5-Hydroxymethylcytosine signals in serum are a predictor of chemoresistance in high-grade serous ovarian cancer.
|